(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.69% $ 41.11
@ $55.32
Выпущен: 13 февр. 2024 @ 19:06
Доходность: -25.68%
Предыдущий сигнал: февр. 13 - 17:30
Предыдущий сигнал:
Доходность: 0.69 %
Live Chart Being Loaded With Signals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France...
Stats | |
---|---|
Объем за сегодня | 253 701 |
Средний объем | 431 255 |
Рыночная капитализация | 2.01B |
EPS | $0 ( 2024-02-27 ) |
Дата следующего отчета о доходах | ( $0 ) 2024-05-07 |
Last Dividend | $0.300 ( 2010-06-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | 15.81 |
ATR14 | $0.0230 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Petersen Floyd F. | Sell | 500 | Common Stock |
2024-03-15 | Zhang Jack Y. | Buy | 722 046 | Common Stock |
2024-03-15 | Zhang Jack Y. | Sell | 408 721 | Common Stock |
2024-03-17 | Zhang Jack Y. | Sell | 15 768 | Common Stock |
2024-03-15 | Zhang Jack Y. | Buy | 310 930 | Common Stock |
INSIDER POWER |
---|
-2.75 |
Last 100 transactions |
Buy: 1 574 905 | Sell: 1 727 474 |
Объем Корреляция
Amphastar Pharmaceuticals Корреляция
10 Самые положительные корреляции | |
---|---|
LMNR | 0.96 |
PDFS | 0.955 |
RCEL | 0.953 |
GEOS | 0.953 |
ALTR | 0.951 |
VTYX | 0.951 |
ERII | 0.95 |
SLMBP | 0.95 |
PANL | 0.946 |
ANSS | 0.945 |
10 Самые отрицательные корреляции | |
---|---|
CSSEP | -0.95 |
NAKD | -0.95 |
ALXO | -0.95 |
MICS | -0.95 |
BLUE | -0.946 |
CBNK | -0.944 |
PMVP | -0.943 |
CMLS | -0.94 |
BWB | -0.94 |
FGBI | -0.939 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Amphastar Pharmaceuticals Корреляция - Валюта/Сырье
Amphastar Pharmaceuticals Финансовые показатели
Annual | 2023 |
Выручка: | $644.40M |
Валовая прибыль: | $343.97M (53.38 %) |
EPS: | $2.85 |
FY | 2023 |
Выручка: | $644.40M |
Валовая прибыль: | $343.97M (53.38 %) |
EPS: | $2.85 |
FY | 2022 |
Выручка: | $498.99M |
Валовая прибыль: | $248.86M (49.87 %) |
EPS: | $1.880 |
FY | 2021 |
Выручка: | $437.77M |
Валовая прибыль: | $199.74M (45.63 %) |
EPS: | $1.350 |
Financial Reports:
No articles found.
Amphastar Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.300 | 2009-06-11 |
Last Dividend | $0.300 | 2010-06-11 |
Next Dividend | $0 | N/A |
Payout Date | 2010-06-30 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.600 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.66 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.09 | |
Div. Directional Score | 7.14 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.213 | 1.500 | 5.73 | 8.60 | [0 - 0.5] |
returnOnAssetsTTM | 0.0909 | 1.200 | 6.97 | 8.36 | [0 - 0.3] |
returnOnEquityTTM | 0.232 | 1.500 | 8.53 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.17 | 0.800 | 4.14 | 3.31 | [1 - 3] |
quickRatioTTM | 1.660 | 0.800 | 4.94 | 3.95 | [0.8 - 2.5] |
cashRatioTTM | 0.641 | 1.500 | 7.55 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.392 | -1.500 | 3.46 | -5.19 | [0 - 0.6] |
interestCoverageTTM | 9.50 | 1.000 | 7.59 | 7.59 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.83 | 2.00 | 8.72 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.03 | 2.00 | 8.48 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.928 | -1.500 | 6.29 | -9.43 | [0 - 2.5] |
grossProfitMarginTTM | 0.541 | 1.000 | 4.32 | 4.32 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.294 | 1.000 | 6.12 | 6.12 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.309 | 1.000 | 9.39 | 9.39 | [0.2 - 2] |
assetTurnoverTTM | 0.426 | 0.800 | -0.494 | -0.395 | [0.5 - 2] |
Total Score | 10.19 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 14.33 | 1.000 | 8.65 | 0 | [1 - 100] |
returnOnEquityTTM | 0.232 | 2.50 | 9.06 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.03 | 2.00 | 8.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.83 | 2.00 | 8.72 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.191 | 1.500 | -2.06 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.285 | 1.000 | 5.38 | 0 | [0.1 - 0.5] |
Total Score | 4.09 |
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа